Richard Adcock, ImmunityBio CEO
ImmunityBio inks royalty deal, private placement to raise $210M for bladder cancer drug combo
ImmunityBio has struck a royalty deal and a private placement to raise up to $320 million as it eyes a potential …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
